PubMed Health⌕ Search

Biomedical subjects

P Biron

Publications and source records attributed to P Biron.

At least 19 recordsLinked to original sources
PubMed1992

Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group.

Data on 49 allogeneic bone marrow transplant (BMT) recipients who developed interstitial pneumonia due to cytomegalovirus (CMV) were collected retrospectively. All patients were treated with ganciclovir and high doses of intravenous immune globulin, although types of immune globulins and schedules of treatment varied. Seventeen (35%) of 49 patients responded to treatment. Thirty days after the diagnosis of interstitial pneumonia, the survival rate among patients was 31%. CMV was detected in 81% of patients on whom autopsies were performed. The survival rate among patients who received total body irradiation (TBI) was significantly lower (11 [27%] of 41) than that among patients who did not receive TBI (six [75%] of eight; odds ratio = 12.3; P = .009). No other factor, including age, grade of graft-versus-host disease, types and dose of immune globulin used, or dose of ganciclovir, was correlated to survival. These results show that although survival of allogeneic BMT recipients with CMV interstitial pneumonia has improved, more than one-half of the patients still died of pneumonia. Thus, both prophylaxis for and treatment of CMV infection must be improved.

Adolescent↗
PubMed1992

[The role of tumor markers in the pre-therapeutic staging of non-small cell bronchial cancer].

A biological cancer marker is a molecule, synthetized from a neoplastic tissue, which is present in the tumor and can be detected in measurable amounts in circulating blood. The natural history, prognosis, heterogeneity of each tumor and the histology of bronchial cancers clearly show the difficulty to establish the role of markers in the management of these tumors, especially for the initial assessment of extension. The analysis of the literature shows that studies on this subject are rare. The use of an isolate marker is not sufficient for a positive diagnosis of non-small-cell bronchial cancer. The use of several markers produces better results. However, no model is accurate enough to formally influence the diagnosis of operability. No isolate or associated marker allows differentiating between small-cell and non-small-cell bronchial cancers. The most interesting two markers finally seem to be ACE and CA 125. All other markers must not be used as a routine during the assessment of non-small-cell bronchial cancers. However, these markers are still important for therapeutic follow-up. Even though they are not predictive of chemosensitivity, and even though their decrease is not regarded as an objective criterion of response, their variations are linked with the response to chemotherapy, and their persistent normalization after surgery is compatible with apparent complete remission. The ACE and CA 125 assays can therefore be used as a reference, in case of initial positive findings, for the subsequent follow-up of the patient.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1979

Familial aggregation of blood pressure and weight in adoptive families. I. Comparisons of blood pressure and weight statistics among families with adopted, natural, or both natural and adopted children.

Tests of homogeneity of means, variances and correlations for systolic blood pressure (BP), diastolic BP and weight among subdivisions of a smple of adoptive families are presented. The means and variances of either type of BP, but not weight, were not significantly heterogeneous among families grouped according to the number of parents and children, natural and/or adopted, in the family unit. Estimates of correlation between family members wree not heterogeneous among subdivisions for each of the three variables. Our results indicate that these data are suitable for a genetic analysis of familial aggregation. Pooled correlations suggest that the degree of resemblance of BP and of weight between family members varies within and across generations. Correlations involving the adoptees were significantly different from zero only for diastolic BP.

Adolescent↗
PubMed1979

Familial aggregation of blood pressure and weight in adoptive families. II. Estimation of the relative contributions of genetic and common environmental factors to blood pressure correlations between family members.

An analysis of the familial aggregation of blood pressure (BP) was conducted to provide estimates of the role of genes and household environment in determining the phenotypic resemblance between biologically related family members. The biological model used for this analysis parameterizes the correlations between family members into the contributions of genetic and environmental variability shared within and across generations. Hypothesis testing about different parameters in the model suggests that shared environment explains larger fractions of the parent-natural child and the full sib correlations for diastolic BP than for systolic BP. For diastolic BP, children in a household share the effects of common environment in addition to the effects which they share with their parents. Dependence of the degree of resemblance between household members on the effects of environmental factors shared within and a-ross generations is not explained by the variability of length of cohabitation among individuals.

Adolescent↗
PubMed1978

Dissociation between clinical and exercise responsiveness to beta-blockade in angina.

Twenty outpatients with mild angina were prescribed placebo tablets b.i.d. for 7 weeks followed by acebutolol, a cardioselective beta-blocker, 200 mg b.i.d. for 21 weeks under single-blind conditions. One graded multistage treadmill test was carried out after each treatment period and an angina diary was filled daily for the 6 months of the trial. Attack frequency declined by 71% from 2.59 per week on placebo to 0.76 per week on acebutolol (p less than 0.05). Exercise duration on the treadmill increased by 56%, from 5.95 minutes on placebo to 9.32 minutes on acebutolol (p less than 0.001). A satisfactory clinical response (50% or greater decline in attack frequency per week) occurred in 15 out of 19 patients (79%; a 100% or greater increase in exercise duration on the treadmill was observed in 10 out of 19 cases (53%). Exercise responsiveness was well predicted by exercise duration on placebo (r = 0.91, p less than 0.0005), patients with the least initial tolerance being the most improved. Clinical responsiveness was not well predicted by initial exercise tolerance (r = 0.38, N;S.) or by the improvement in exercise tolerance (r = 0.33, N.S.). It is concluded that acebutolol substantially reduces anginal attack frequency even in patients in whom exercise tolerance is not significantly improved, at the dose of 400 mg/day.

Acebutolol↗